WASHINGTON (Reuters) - U.S. regulators said on Monday that Johnson & Johnson added new warnings to its schizophrenia drug, Haldol, about the potential risk of death and of dangerous heart conditions observed in some patients.
WASHINGTON (Reuters) - U.S. regulators said on Monday that Johnson & Johnson added new warnings to its schizophrenia drug, Haldol, about the potential risk of death and of dangerous heart conditions observed in some patients.
